| Abstrakt: |
A recent study conducted by Columbia University focused on the development of probiotic Escherichia coli Nissle 1917 as a platform for cancer vaccination. The engineered probiotic was designed to enhance the production and delivery of tumor-specific neoantigens, resulting in potent and specific T cell-mediated anticancer immunity in murine models. The research, supported by various institutions and foundations, highlights the potential of bacterial vectors as precision cancer vaccines. The study's findings have been published in Nature and emphasize the importance of leveraging living medicines for inducing effective and durable systemic antitumor immunity. [Extracted from the article] |
